|drug3302||Reference: Favipiravir 200 mg (Avigan) Wiki||1.00|
|drug3957||Test: Favipiravir 200 mg (LOQULAR) Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This is a study to test a new vaccine (Covax-19) against COVID-19. COVID-19 is a potentially deadly disease that is caused by a new strain of coronavirus called SARS-CoV-2. To date, SARS-CoV-2 has infected over 4 million people worldwide resulted in the deaths of over three hundred thousand people.
Description: Incidence of Adverse Events 1 week post immunisationMeasure: Incidence of Adverse Events Time: 1 weeks post immunisation
Description: COVID19 neutralizing antibody titers post immunisationMeasure: COVID19 neutralizing antibody titers Time: 2 weeks post second immunisation
Description: Frequency of COVID19 spike specific T cells 3 weeks post second immunisationMeasure: COVID19 T cell immunogenicity Time: 3 weeks post second immunisation
Description: COVID19 spike specific antibody titers 6 months post second immunisationMeasure: Durability of antibody response Time: 6 months post immunisation
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports